Tracy Palmer Berns has joined rare disease drug developer Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) as chief compliance officer, the same role she held most recently at AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]). Her experience also includes compliance and regulatory positions at Medtronic (NYSE: [[ticker:MDT]]) and Covidien, which Medtronic acquired in 2015. Boston-based Akcea has two commercialized products: hereditary transthyretin amyloidosis treatment inotersen (Tegsedi) and volanesorsen (Waylivra) for familial chylomicronemia syndrome.